A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone
Public ClinicalTrials.gov record NCT02066389. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Investigate the Safety and Efficacy of ABT-494 With Background Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis (RA) Who Have Had an Inadequate Response to MTX Alone
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of the study was to compare the safety and efficacy of multiple doses of upadacitinib versus placebo in adults with moderately to severely active rheumatoid arthritis (RA) on stable background methotrexate therapy who had not shown an adequate response to methotrexate alone.
Study identification
- NCT ID
- NCT02066389
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 25, 2014
- Primary completion
- Jul 1, 2015
- Completion
- Jul 1, 2015
- Last update posted
- Jul 29, 2021
2014 – 2015
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| C.V. Mehta MD, Med Corporation /ID# 126380 | Hemet | California | 92543 | — |
| Omega Research Consultants, LLC /ID# 125780 | DeBary | Florida | 32713-2260 | — |
| Lovelace Scientific Resources /ID# 127324 | Venice | Florida | 34292 | — |
| North Georgia Rheumatology Grp /ID# 125779 | Lawrenceville | Georgia | 30045 | — |
| PRN Professional Research Network of Kansas, LLC /ID# 126148 | Wichita | Kansas | 67205 | — |
| The Center for Rheumatology & /ID# 127323 | Wheaton | Maryland | 20902 | — |
| Summit Medical Group /ID# 125776 | Clifton | New Jersey | 07012 | — |
| Arthritis and Osteo Assoc /ID# 134994 | Las Cruces | New Mexico | 88011 | — |
| Altoona Ctr Clinical Res /ID# 125777 | Duncansville | Pennsylvania | 16635 | — |
| Emkey Arthritis and Osteo Clin /ID# 134716 | Wyomissing | Pennsylvania | 19610 | — |
| Accurate Clinical Research /ID# 126535 | Houston | Texas | 77034 | — |
| Mountain State Clinical Resear /ID# 127089 | Clarksburg | West Virginia | 26301 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 51 non-U.S. sites.
Recently updated Rheumatoid Arthritis trials
Other public records listing Rheumatoid Arthritis. Sorted by last update posted; newest first. Not a recommendation.
- NCT07137598: A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) Recruiting
- NCT04817969: Persona Ti-Nidium Post-Market Clinical Follow-up Active, not recruiting
- NCT07620392: An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants With Rheumatoid Arthritis Recruiting
- NCT05936970: Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to a DMARD Starting a New bDMARD or tsDMARD Treatment +/- csDMARD Active, not recruiting
- NCT07704580: Phase 1b/2 Study of IV Sarilumab in Adult With RA Recruiting
- NCT07293871: Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02066389, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 29, 2021 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02066389 live on ClinicalTrials.gov.